Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Semaglutide's heart benefits go beyond the scale. A new analysis of the SELECT trial found that weight loss alone can't fully explain semaglutide's 20% reduction in major cardiovascular events. Even when all known risk factors were combined, less than half of the heart benefit was accounted for — suggesting the drug may have direct cardiovascular effects not yet fully understood.
A new analysis of the landmark SELECT trial, published in the European Heart Journal, reveals that semaglutide's cardiovascular (CV) benefits can't be pinned on weight loss — or any single risk factor — alone. Researchers analyzed data from 17,604 adults with obesity and established heart disease (but no diabetes) to understand why semaglutide 2.4 mg (Wegovy) cut the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo.
Semaglutide improved all 12 tracked risk factors — including body weight, waist circumference, blood pressure, hsCRP, and HbA1c — but even combining all of them explained only about 31% of the CV benefit. That leaves a significant portion of the drug's heart-protective effect unexplained, pointing to possible mechanisms like anti-inflammatory effects or direct action on blood vessels and heart muscle.
By the Numbers:
Why it matters: These findings reframe how clinicians should think about semaglutide — not just as a weight-loss drug, but as a potential cardiovascular therapy in its own right. For patients with obesity and high CV risk, the drug's benefits may persist even when weight loss is modest, warranting further research into its broader mechanisms.
